Page 167 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Rituximab intensification during R-CHOP in DLBCL Table 3. Grade 3-4 adverse events during cycles 1-8 in all patients.
Adverse Event
All toxicity Neutropenia Febrile neutropenia Anemia Thrombocytopenia Infection Neurologic toxicity GI
Cardiac toxicity
No. (%)
Grade 3
70 (25) 23 (8)
—
44 (15) 13 (5) 57 (20) 38 (13) 36 (13) 11 (4)
Grade 4
127 (45) 91 (32) 3 (1)
11 (4) 19 (7) 13 (5)
2 (1) 4 (1) —
Grade 3
70 (24) 29 (10)
—
49 (17) 20 (7) 64 (22) 37 (13) 31 (11) 11 (4)
Grade 4
146 (51) 107 (37) 1 (0)
5 (2)
16 (6) 7 (2) 3 (1) 6 (2) 3 (1)
R-CHOP-14 RR-CHOP-14 (n = 285) (n = 288)
NOTE. Data are No. of patients (%) with an event. Patients could have the same type of event more than once.
Abbreviations: R-CHOP, rituximab on day 1 of each cycle plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm A); RR-CHOP, rituximab on days 1 and 8 of first 4 cycles and day 1 of remaining cycles plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm B).
Table 4. Grade 3-4 adverse events during cycles 1-4 in patients age 18-65 versus 66-80 years.
No. (%)
Age 18-65 years
Age 66-80 years
Adverse Event R-CHOP-14 RR-CHOP-14 R-CHOP-14 RR-CHOP-14 (n = 140) (n = 149) (n = 145) (n = 139)
All toxicitya Neutropeniab Febrile neutropenia Anemia Thrombocytopenia Infectionc Neurologic toxicity GI
Cardiac toxicity
NOTE. Data are No. once.
Grade 3
30 (21) 12 (9)
— 11 (8)
2 (1) 13 (9) 5 (4)
15 (11) 1 (1)
of patients
Grade 4
42 (30) 33 (24) 1 (1)
3 (2) 5 (4) 3 (2) —
Grade 3
32 (21) 10 (7) —
Grade 4
46 (31) 38 (26)
—
2 (1) 2 (1) 1 (1)
— — —
Grade 3
26 (18) 6 (4) —
21 (14) 7 (5) 23 (16) 11 (8)
Grade 4
58 (40) 41 (28) 1 (1)
4 (3) 6 (4) 4 (3)
— — —
Grade 3
23 (17) 14 (10)
—
18 (13)
7 (5) 30 (22) 8 (6) 17 (12)
Grade 4
78 (56) 48 (35) 1 (1)
3 (2) 5 (4) 4 (3) —
1 (1) ——
14 (10) 2 (1)
3 (2) 2 (1)
11 (7) 5 (3) 17 (11) 8 (5) 5 (3)
7 (5)
(%) with an event. Patients could have the same type of event more than
Abbreviations: R-CHOP, rituximab on day 1 of each cycle plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm A); RR-CHOP, rituximab on days 1 and 8 of first 4 cycles and day 1 of remaining cycles plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm B).
a In patients age 66-80 years: grade 4, 40% v 56% (P = .007); grade 3-4, 58% v 73% (P = .009).
b In patients age 66-80 years: grade 4, 28% v 35% (P = .26); grade 3-4, 32% v 45% (P = .04). c In patients 66-80 years: grade 4, 3% v 3% (P = 1.00); grade 3-4, 19% vs 25% (P = .23).
165
6b